Clinical Trials Sponsored by SEBASTIAN ROCHE

Total 3072 results

Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Solid Tumors

United States, Spain, Belgium, Denmark, Canada, Australia
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, Hungary, Brazil, Finland, Italy, Germany, Romania, Lithuania, France, Greece, Peru, Portugal, Spain, Switzerland, Bulgaria, Ukraine, Israel, Poland, Austria, New Zealand, Netherlands, Belgium, Mexico, United... and more
Hoffmann-La Roche

Withdrawn

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)

Medullary Thyroid Cancer

Spain
Hoffmann-La Roche

Completed

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab (ALTIMETER)

Diabetic Macular Edema

Germany, United States, United Kingdom, Argentina, Canada, Italy, Poland
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Belgium, China, France, Netherlands, Japan, Hungary, Russian Federation, Taiwan, Ireland, Romania, Israel, Latvia, Italy, Portugal, Austria, Bulgaria, Chile, Ukraine, Argenti... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS)

Non-Small Cell Lung Cancer

Canada, Belgium, Brazil, China, Denmark, Portugal, Spain, United Kingdom, Argentina, Bulgaria, Colombia, Germany, India, Ireland, Italy, Luxembourg, Mexico, Poland, Romania, Slovakia, Switzerland, Vietnam, Kazakhstan, Czechia
Hoffmann-La Roche

Terminated

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Crohn Disease

United States, Israel, Spain, United Kingdom, Canada, Australia, Austria, Czechia, France, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Korea, Republic of, Germany, Bulgaria, Croatia, Hungary, Poland, Ukraine and more
Hoffmann-La Roche

Completed

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States, Korea, Republic of, Italy, Australia, Spain
Hoffmann-La Roche

Completed

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom, Australia, Belgium, Brazil, Croatia, France, Canada, Slovakia, Germany, Netherlands, Norway, Italy, Poland, Switzerland, Romania, Bulgaria, Spain, Mexico, Austria, Portugal, Turkey, Sweden, Argentina, Denmark and more
Hoffmann-La Roche

Completed

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

Healthy Male Subjects

Australia, New Zealand
Hoffmann-La Roche

Completed

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Hoffmann-La Roche

Completed

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder

United States, Japan, Ukraine, Russian Federation
Hoffmann-La Roche

Completed

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Hoffmann-La Roche

Terminated

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Autoimmune Hepatitis | Autoimmune Chronic Hepatitis

Canada, United Kingdom, Korea, Republic of, Australia, Germany, Italy, Netherlands, Portugal
Hoffmann-La Roche

Completed

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

Huntington Disease

United States, Canada, Netherlands, Germany, Spain, United Kingdom, Austria, Italy
Hoffmann-La Roche

Terminated

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)

Digestive System Diseases | Gastrointestinal Diseases | Melanoma | Sarcoma | Neoplasms | Respiratory Tract Diseases | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Head and Neck Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms and other conditions

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Solid Tumors

Belgium, United States, Australia, Denmark, Spain, United Kingdom
Hoffmann-La Roche

Terminated

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Renal Cell Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Argentina, Australia, Belgium, Brazil, China, Denmark, Ireland, Spain, Japan, Netherlands, Chile, Czechia, Italy, France, Israel, Turkey, Germany, Austria, Taiwan, Serbia, Poland, Thailan... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (MAURIS)

Small Cell Lung Carcinoma

Italy
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

China
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)

Diabetic Macular Edema

Korea, Republic of, United States, United Kingdom, Brazil, China, Canada, Argentina, Australia, Denmark, France, Italy, Poland, Spain, Germany, Singapore, Czechia, Hong Kong, Portugal, Russian Federation, Taiwan, Hungary, Switzerland and more
Hoffmann-La Roche

Completed

A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device. (Lupa-01)

Non-Small Cell Lung Cancer (NSCLC)

Spain
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa)

Early Breast Cancer

France, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (PEONY)

Breast Cancer

China, Korea, Republic of, Taiwan, Thailand
AbbVie
Roche-Genentech

Completed

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Non-Hodgkin's Lymphoma | Neuroblastoma | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Malignancies

United States, Australia, Canada, France, Germany, Netherlands, Switzerland, United Kingdom
Hoffmann-La Roche

Terminated

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Schizophrenia, Schizoaffective Disorder

United States, Spain, Japan, Ukraine
Hoffmann-La Roche

Completed

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Hoffmann-La Roche

Completed

A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Breast Cancer

Spain
Hoffmann-La Roche

Completed

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Urothelial Carcinoma

Argentina
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Diffuse, Large B-Cell, Lymphoma

China
Hoffmann-La Roche

Completed

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)

Prostatic Neoplasms, Castration-Resistant

United States, Korea, Republic of, Belgium, United Kingdom, Canada, China, Denmark, France, Greece, Poland, Spain, Italy, Czechia, Japan, Switzerland, Australia, Germany, Austria, Hungary, Russian Federation, Taiwan
Hoffmann-La Roche

Completed

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

Korea, Republic of, United Kingdom, Denmark, France, Spain, Canada, United States, Germany, Italy
Hoffmann-La Roche

Completed

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

Alzheimer's Disease

Canada, United States, Spain, Korea, Republic of, Belgium, United Kingdom, Australia, Germany, Portugal, Argentina, Bulgaria, Denmark, Finland, France, Hungary, Italy, Japan, Netherlands, Russian Federation, Sweden, Switzerland, T...
Hoffmann-La Roche

Completed

A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis
Hoffmann-La Roche

Completed

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

Asthma

Korea, Republic of, United States, Belgium, Czechia, Germany, Peru, Bulgaria, Russian Federation, Argentina, Ukraine, Canada, Poland, South Africa, New Zealand, Romania
Hoffmann-La Roche

Completed

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Solid Tumor, Unspecified, Adult

United States
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

Belgium, United States, Israel, China, Australia, Germany, Russian Federation, Ukraine, United Kingdom, Poland, Bulgaria, Italy
Hoffmann-La Roche

Completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Italy, Korea, Republic of, Australia, Canada, Czechia, Spain, United Kingdom, France, Germany, Hungary, Turkey, Netherlands
Hoffmann-La Roche

Completed

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)

Solid Tumors

United States, Spain, Germany, France, Israel, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Carcinoma, Non-Small Cell Lung | Urothelial Carcinoma | Triple Negative Breast Carcinoma

Korea, Republic of
Hoffmann-La Roche

Terminated

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy (Veronica)

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Canada, United States, United Kingdom, Australia, Germany
Hoffmann-La Roche

Completed

A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United States, Canada, United Kingdom
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Breast Cancer

United States, France, Czechia, Italy, Korea, Republic of, Australia, Belgium, Brazil, Canada, Germany, Guatemala, Hong Kong, Hungary, Panama, Peru, Poland, Spain, Taiwan, United Kingdom, Colombia, Bosnia and Herzegovina, Chile, El... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL)

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Argentina, Brazil, China, Denmark, Greece, Panama, Spain, United Arab Emirates, United Kingdom, Mexico, Poland, Peru, Philippines, Costa Rica, Malaysia, Morocco, Latvia, Lebanon, Sweden, Slovenia, Colombia, Guatemala
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

France, United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Huntington's Disease

Germany, Canada, United Kingdom
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel

Clinical Trials Sponsored by SEBASTIAN ROCHE

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations